Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA

‘Biobetter’ Submitted To FDA As Biologic Via 351(a) Pathway, Not As A Biosimilar

 
• By David Wallace
  
FDA building.
Celltrion has filed its subcutaneous infliximab with the FDA • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products